YD Bio Limited Ordinary Shares
YDES · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $1 | $0 | $0 | $0 |
| % Growth | 45.8% | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 30.4% | 43.8% | – | – |
| R&D Expenses | $0 | $0 | $0 | $0 |
| G&A Expenses | $1 | $0 | $0 | $0 |
| SG&A Expenses | $1 | $0 | $2 | $2 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | -$0 | $0 | $0 | $0 |
| Operating Expenses | $2 | $0 | $2 | $2 |
| Operating Income | -$1 | -$0 | -$2 | -$2 |
| % Margin | -286.5% | -2.8% | – | – |
| Other Income/Exp. Net | $0 | $0 | $6 | $10 |
| Pre-Tax Income | -$1 | $0 | $4 | $9 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$1 | $0 | $4 | $9 |
| % Margin | -276.6% | 3.9% | – | – |
| EPS | -0.56 | 0 | 0.41 | 0.59 |
| % Growth | -280,100% | -100% | -30.5% | – |
| EPS Diluted | -0.56 | 0 | 0.41 | 0.59 |
| Weighted Avg Shares Out | 4 | 70 | 9 | 15 |
| Weighted Avg Shares Out Dil | 4 | 70 | 9 | 15 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$1 | $0 | $4 | $9 |
| % Margin | -251% | 6.4% | – | – |